NEW YORK, Nov. 12, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Sarepta Therapeutics, Inc. ("Sarepta Therapeutics" or the "Company") (NasdaqGM: SRPT). Such investors are advised to contact Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman at email@example.com or 212-697-6484.
The investigation concerns whether Sarepta Therapeutics and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On November 12, 2013 shares of Sarepta Therapeutics fell $22.55 or 61.68% during intraday trading to trade at $14.01, after the FDA raised concerns about the trial results for its experimental Duchenne muscular dystrophy drug, eteplirsen. The FDA called an application to sell eteplirsen "premature," the Company said in a statement.
If you are aware of any facts relating to this investigation, or purchased shares of Sarepta Therapeutics, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes. Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Eitan Kimelman 212-697-6484 email@example.com